by David Wallace Two-year results from the Phase 3 SURPASS-ET trial suggest that earlier initiation of ropeginterferon alfa-2b may provide deeper molecular responses and more durable disease control for some patients with high-risk essential thrombocythemia (ET). The findings were presented by Harinder Gill, MD, at the 2026 European Hematology Association Congress in Stockholm. What Did […]
From Questions to Confidence: Piecing Together the Facts About Essential Thrombocythemia
Sponsored Post Being diagnosed with a rare, chronic blood cancer like essential thrombocythemia, or ET, can feel overwhelming and isolating. In the United States, approximately 24 out of every 100,000 people are currently living with ET. Because ET is uncommon, it may be hard to know where to turn for clear, trustworthy information—especially early in […]
Michael’s MPN Story
by Michael Movsky My MPN journey began at the hematologist’s office on a pleasant March day in 2018, when she confirmed a diagnosis of Essential Thrombocytosis (ET) through various factors, including the detection of the JAK 2 mutation…at which point I was handed an informational booklet on the topic from the Leukemia and Lymphoma Society. […]